33 results on '"Xia, W."'
Search Results
2. Abstract P3-07-21: Non-alcoholic fatty liver disease induced by selective estrogen receptor modulators is a protective factor for breast cancer survival
- Author
-
Wang, S, primary, Zheng, Q, additional, Nie, M, additional, Xu, F, additional, Xia, W, additional, Yuan, Z, additional, Peng, R, additional, An, X, additional, Qin, T, additional, and Qin, G, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Abstract P4-08-03: The impact of the heregulin-HER receptor signaling axis on response to HER tyrosine kinase inhibitors.
- Author
-
Gwin, WR, primary, Liu, L, additional, Zhao, S, additional, Xia, W, additional, and Spector, NL, additional
- Published
- 2012
- Full Text
- View/download PDF
4. Abstract P4-08-07: Novel insight into the tumor “flare” phenomenon and lapatinib resistance
- Author
-
Piede, JA, primary, Zhao, S, additional, Liu, L, additional, Lyerly, HK, additional, Osada, T, additional, Wang, T, additional, Xia, W, additional, and Spector, N, additional
- Published
- 2012
- Full Text
- View/download PDF
5. The impact of the heregulin-HER receptor signaling axis on response to HER tyrosine kinase inhibitors.
- Author
-
Gwin, W. R., Liu, L., Zhao, S., Xia, W., and Spector, N. L.
- Subjects
- *
PROTEIN-tyrosine kinases , *LIGANDS (Biochemistry) , *CANCER cell proliferation , *CANCER research , *LAPATINIB - Abstract
Background: HER receptor tyrosine kinases (EGFR/HER1; HER2; HER3; HER4) and their soluble ligands represent a robust system involved in the regulation of a diverse array of cellular processes. Deregulation of HER receptors, notably HER2, has been linked to the initiation and progression of breast cancer and other solid tumors. Relatively less is known about the role of HER receptor soluble ligands in tumorigenesis and responsiveness to HER targeted therapies. Here we will discuss the impact of the HER3 ligand heregulin (HRG) on the sensitivity of breast cancers to HER tyrosine kinase inhibitors (TKIs), and identify TKI strategies to treat HRG-driven breast cancers. Methods: The effects of exogenous HRG (50ng/ml) on the antitumor activity of a panel of TKIs with different enzymatic properties e.g. a reversible, selective inhibitor (lapatinib) and irreversible, pan-HER inhibitors (neratinib; CI-1033) were assessed in HER2+ breast cancer (BC) cell lines. The concentration of TKIs used was in the 1--2.5 uM range, and cells were treated over a 72 hr course. Vehicle treatment alone served as controls. The impact of the above mentioned treatments on total HER receptor and specific EGFR, HER2, and HER3 phosphotyrosine sites, in addition to the phosphorylation state of components of downstream MAPK and PI3K signaling pathways was analyzed through western blot. In addition to studying the effects of exogenous HRG, the impact of TKIs on a model of triple negative BC (TNBC) known to produce HRG in an autocrine manner was also evaluated. QRT-PCR was used to assess the effects of TKIs on HER receptor mRNA levels. Results: Lapatinib inhibited proliferation and phosphorylation of EGFR, HER2, HER3, and downstream MAPK and PI3K signaling pathways in HER2+ SKBR3 and BT474 cell lines. Pre-treatment with HRG abrogated the antitumor effects of a therapeutic concentration of lapatinib (1 uM), and reversed the inhibitory effects of lapatinib on the phosphorylation of HER receptors and components of their downstream signaling pathways e.g. Erk1/2 and Akt. Neratinib also blocked proliferation and phosphorylation in HER2+ BC cells. In contrast to lapatinib, the antitumor effects of neratinib were not reversed by exogenous HRG. Interestingly, treatment with neratinib and similar pan-HER irreversible TKIs, but not reversible TKIs, resulted in loss of HER2 and EGFR protein expression. QRT-PCR was used to evaluate if this effect was at the level of transcription. Furthermore, neratinib inhibited cell proliferation and blocked EGFR signaling in a TNBC model driven by autocrine produced HRG. Conclusions: Our findings suggest that HRG is a mediator of therapeutic resistance to lapatinib in HER2+ and TNBC. Neratinib demonstrates profound effects on HER signaling by markedly reducing HER2 and EGFR protein expression and blocking the protumorigenic effects of autocrine or paracrine expression of HRG. In contrast to HRG, we previously showed that EGF, an EGFR specific ligand did not reverse the antitumor effects of lapatinib in breast cancer cells. Thus, the selection of HER targeted therapies in a given tumor should take into account not only the HER receptor expression profile, but also the presence of autocrine or paracrine derived ligands activating HER receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Novel insight into the tumor "flare" phenomenon and lapatinib resistance.
- Author
-
Piede, J. A., Zhao, S., Liu, L., Lyerly, H. K., Osada, T., Wang, T., Xia, W., and Spector, N.
- Subjects
- *
DRUG resistance in cancer cells , *LAPATINIB , *PROTEIN-tyrosine kinases , *CANCER treatment , *BREAST cancer - Abstract
BACKGROUND: Resistance to lapatinib generally develops in approximately half of patients within one year of initiating treatment. When lapatinib is withdrawn, there is often a rapid progression of disease which is associated with high mortality rates. This "flare" phenomenon has also been observed upon discontinuation of other tyrosine kinase inhibitors (TKIs) in lung cancer, renal cell carcinoma, and gastrointestinal stromal tumors. METHODS: Using the HER2+ cell lines SKBR3 and BT474, we developed both in vitro and in vivo models demonstrating lapatinib resistance and the tumor "flare" phenomenon. Parental HER2+ cell lines were gradually exposed to increasing doses of lapatinib (100nM to 5uM) to develop a lapatinib-resistant form which was ultimately maintained in 1uM of lapatinib. Lapatinib-"released" cell lines were developed by removing lapatinib exposure from resistant cell lines and allowing the cells to grow for at least two weeks. Cell lines were grown in vitro using traditional monolayer cell culturing techniques and mammosphere technology. A comprehensive analysis of parental, lapatinib-resistant, and lapatinib-released cell lines was performed using microscopy, protein/phosphoprotein analysis, cell cycle, cancer stem cell markers by FACS, and invasion assays. Parental cells served as the control in all experiments. In vivo models were performed by injecting 10,000 cells of parental, resistant, and released cell lines in the mammary fat pads of SCID mice. Tumors were surgically resected after approximately sixty days and volume recorded. All experiments were repeated three times and calculated for statistical significance. RESULTS: Cell cycle analysis and proliferation assays demonstrate that lapatinib-resistant and released cell lines continue to proliferate despite the addition of 1uM lapatinib. Released cells also demonstrate less of a response to retreatment with lapatinib. Tumor volume of lapatinib-released cell lines were significantly larger than parental and resistant counterparts [parental: 39.9mm³, SD 9.48; resistant: 71.8mm³, SD 62.33; released: 943.4mm³, SD 100.1] and this difference was statistically significant (p < 0.01). After three series of passages, mammosphere forming efficiency (MFE) was higher among lapatinib-released cell lines [parental: 1.03%; resistant: 1.93% released: 7.23%] and was statistically significant (p <0.01). Lapatinib-released mammosphere phenotypes appeared larger and less organized than the parental and resistant counterparts. MFE did not correlate with ALDH expression by FACS, and expression varied based on cell line. Western blot analysis revealed loss of E-cadherin among lapatinib-released cells which was not demonstrated in parental or resistant counterparts. Invasion assays demonstrated increased migration among resistant and released cell lines. CONCLUSIONS: We demonstrate the first in vitro and in vivo models of the tumor "flare" phenomenon using HER2+ breast cancer cell lines. This model demonstrates that lapatinib -resistant cells released from the exposure to lapatinib are propelled into a unique and more aggressive phenotype. This model has potential to elucidate new mechanisms of resistance to TKI therapy and provide novel preclinical data that may help in the understanding of disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer.
- Author
-
Pan P, Qin G, Wang B, Yu H, Chen J, Liu J, Bing K, Shen J, Ren D, Zhao Y, Xia W, Li H, Wu H, and Zhou Y
- Subjects
- Humans, Cytosol metabolism, Phospholipases A2, Cytosolic genetics, Phospholipids metabolism, Adenocarcinoma genetics, Arachidonic Acid metabolism, Histone Deacetylases genetics, Pancreatic Neoplasms genetics
- Abstract
HDAC5 is a class IIa histone deacetylase member that is downregulated in multiple solid tumors, including pancreatic cancer, and loss of HDAC5 is associated with unfavorable prognosis. In this study, assessment of The Cancer Genome Atlas pancreatic adenocarcinoma dataset revealed that expression of HDAC5 correlates negatively with arachidonic acid (AA) metabolism, which has been implicated in inflammatory responses and cancer progression. Nontargeted metabolomics analysis revealed that HDAC5 knockdown resulted in a significant increase in AA and its downstream metabolites, such as eicosanoids and prostaglandins. HDAC5 negatively regulated the expression of the gene encoding calcium-dependent phospholipase A2 (cPLA2), the key enzyme in the production of AA from phospholipids. Mechanistically, HDAC5 repressed cPLA2 expression via deacetylation of GATA1. HDAC5 knockdown in cancer cells enhanced sensitivity to genetic or pharmacologic inhibition of cPLA2 in vitro and in vivo. Fatty acid supplementation in the diet reversed the sensitivity of HDAC5-deficient tumors to cPLA2 inhibition. These data indicate that HDAC5 loss in pancreatic cancer results in the hyperacetylation of GATA1, enabling the upregulation of cPLA2, which contributes to overproduction of AA. Dietary management plus cPLA2-targeted therapy could serve as a viable strategy for treating HDAC5-deficient pancreatic cancer patients., Significance: The HDAC5-GATA1-cPLA2-AA signaling axis regulates sensitivity to fat restriction plus cPLA2 inhibition in pancreatic ductal adenocarcinoma, proposing dietary management as a feasible strategy for treating a subset of patients with pancreatic cancer., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
8. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
- Author
-
Yang WH, Cha JH, Xia W, Lee HH, Chan LC, Wang YN, Hsu JL, Ren G, and Hung MC
- Subjects
- Animals, Autocrine Communication immunology, Female, Humans, Immunologic Surveillance immunology, Immunotherapy methods, Mice, Mice, Inbred BALB C, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Paracrine Communication immunology, Receptors, Eph Family immunology, Signal Transduction immunology, Transcriptional Activation immunology, B7-H1 Antigen immunology, Breast Neoplasms immunology, Up-Regulation immunology
- Abstract
Programmed death-ligand 1 (PD-L1) is a well-known immune checkpoint protein that helps cancer cells evade immune response. Anti-PD-L1 immune therapy has been approved for the treatment of several advanced human cancers. Therefore, further understanding of the regulatory mechanisms of PD-L1 is critical to improve PD-L1-targeting immunotherapy. Recent studies indicated that contact-dependent pathways may regulate anticancer immunity, highlighting the importance of cell contact-induced signaling in cancer immunity. Here, we show that tumor cell contact upregulates PD-L1 expression and reduces T-cell-mediated cell killing through the membrane receptor tyrosine kinase ephrin receptor A10 (EphA10), which is not expressed in normal tissues except testis and is known to mediate cell contact-dependent juxtacrine signaling. Knockout of EphA10 in tumor cells increased T-cell-mediated antitumor immunity in syngeneic mouse models. EphA10 expression also correlated positively with PD-L1 in human breast tumor tissues. Together, our data reveal that in addition to paracrine/autocrine signaling, cell contact-mediated juxtacrine signaling also promotes PD-L1 expression, implying that tumor cells may escape immune surveillance via this mechanism and that targeting EphA10 to boost antitumor immunity may be a new immune checkpoint blockade strategy for female patients with breast cancer. Significance: Regulation of PD-L1 expression by cell contact-mediated signaling promotes immune escape in breast cancer and may lead to the development of an immunotherapy with less adverse effects in female patients. Cancer Res; 78(14); 3761-8. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
9. The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma.
- Author
-
Qiu M, Xia W, Chen R, Wang S, Xu Y, Ma Z, Xu W, Zhang E, Wang J, Fang T, Hu J, Dong G, Yin R, Wang J, and Xu L
- Subjects
- A549 Cells, Animals, Carcinogenesis genetics, Cell Line, Tumor, DNA Copy Number Variations genetics, Female, Gene Expression Regulation, Neoplastic genetics, Humans, Male, Mice, Mice, Inbred BALB C, Mice, Nude, MicroRNAs genetics, RNA, Circular, RNA, Small Interfering genetics, Adenocarcinoma of Lung genetics, Cell Proliferation genetics, Isoenzymes genetics, Lung Neoplasms genetics, Protein Kinase C genetics, RNA genetics
- Abstract
Somatic copy number variations (CNV) may drive cancer progression through both coding and noncoding transcripts. However, noncoding transcripts resulting from CNV are largely unknown, especially for circular RNAs. By integrating bioinformatics analyses of alerted circRNAs and focal CNV in lung adenocarcinoma, we identify a proto-oncogenic circular RNA (circPRKCI) from the 3q26.2 amplicon, one of the most frequent genomic aberrations in multiple cancers. circPRKCI was overexpressed in lung adenocarcinoma tissues, in part due to amplification of the 3q26.2 locus, and promoted proliferation and tumorigenesis of lung adenocarcinoma. circPRKCI functioned as a sponge for both miR-545 and miR-589 and abrogated their suppression of the protumorigenic transcription factor E2F7 Intratumor injection of cholesterol-conjugated siRNA specifically targeting circPRKCI inhibited tumor growth in a patient-derived lung adenocarcinoma xenograft model. In summary, circPRKCI is crucial for tumorigenesis and may serve as a potential therapeutic target in patients with lung adenocarcinoma. Significance: These findings reveal high expression of the circular RNA circPRKCI drives lung adenocarcinoma tumorigenesis. Cancer Res; 78(11); 2839-51. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
10. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.
- Author
-
Wang Y, Hsu JM, Kang Y, Wei Y, Lee PC, Chang SJ, Hsu YH, Hsu JL, Wang HL, Chang WC, Li CW, Liao HW, Chang SS, Xia W, Ko HW, Chou CK, Fleming JB, Wang H, Hwang RF, Chen Y, Qin J, and Hung MC
- Subjects
- Adenocarcinoma pathology, Humans, Methylation, Pancreatic Neoplasms pathology, Signal Transduction, Transfection, Zinc Finger Protein GLI1 metabolism, Pancreatic Neoplasms, Adenocarcinoma genetics, Carcinogenesis genetics, Pancreatic Neoplasms genetics, Zinc Finger Protein GLI1 genetics
- Abstract
The oncogenic transcription factor Gli1 is a critical effector in the Hedgehog (Hh) pathway, which is necessary for the development and progression of pancreatic ductal adenocarcinoma (PDAC). Although TGFβ and K-Ras are known regulators of Gli1 gene transcription in this setting, it is not understood how Gli1 functional activity is regulated. Here, we report the identification of Gli1 as a substrate for the protein arginine N-methyltransferase PRMT1 in PDAC. We found that PRMT1 methylates Gli1 at R597, promoting its transcriptional activity by enhancing the binding of Gli1 to its target gene promoters. Interruption of Gli1 methylation attenuates oncogenic functions of Gli1 and sensitizes PDAC cells to gemcitabine treatment. In human PDAC specimens, the levels of both total Gli1 and methylated Gli1 were correlated positively with PRMT1 protein levels. Notably, PRMT1 regulated Gli1 independently of the canonical Hh pathway as well as the TGFβ/Kras-mediated noncanonical Hh pathway, thereby signifying a novel regulatory mechanism for Gli1 transcriptional activity. Taken together, our results identified a new posttranslational modification of Gli1 that underlies its pivotal oncogenic functions in PDAC. Cancer Res; 76(23); 7049-58. ©2016 AACR., Competing Interests: The authors have declared that no conflict of interest exists., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
11. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation.
- Author
-
Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, and Hung MC
- Subjects
- Animals, Cell Line, Tumor, Cell Movement drug effects, Cell Movement physiology, Epithelial-Mesenchymal Transition drug effects, Female, Heterocyclic Compounds, 3-Ring pharmacology, Humans, Mice, Mice, Inbred BALB C, Phosphorylation drug effects, Proteolysis drug effects, Resveratrol, Signal Transduction drug effects, Signal Transduction physiology, Stilbenes pharmacology, beta-Transducin Repeat-Containing Proteins metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, Epithelial-Mesenchymal Transition physiology, Phosphorylation physiology, Proto-Oncogene Proteins c-akt metabolism, Twist-Related Protein 1 metabolism
- Abstract
Epithelial-to-mesenchymal transition (EMT) is an essential physiologic process that promotes cancer cell migration, invasion, and metastasis. Several lines of evidence from both cellular and genetic studies suggest that AKT1/PKBα, but not AKT2 or AKT3, serves as a negative regulator of EMT and breast cancer metastasis. However, the underlying mechanism by which AKT1 suppresses EMT remains poorly defined. Here, we demonstrate that phosphorylation of Twist1 by AKT1 is required for β-TrCP-mediated Twist1 ubiquitination and degradation. The clinically used AKT inhibitor MK-2206, which possesses higher specificity toward AKT1, stabilized Twist1 and enhanced EMT in breast cancer cells. However, we discovered that resveratrol, a naturally occurring compound, induced β-TrCP-mediated Twist1 degradation to attenuate MK-2206-induced EMT in breast cancer cells. Taken together, our findings demonstrate that resveratrol counteracts the unexpected metastatic potential induced by anti-AKT therapy and therefore suggest that the addition of resveratrol to an anti-AKT therapeutic regimen may provide extra support for limiting EMT., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
12. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.
- Author
-
Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, and Hung MC
- Subjects
- Aerobiosis, Animals, Cell Line, Tumor, Female, Humans, Mice, Mice, Inbred BALB C, Pyruvate Kinase metabolism, Triple Negative Breast Neoplasms immunology, Triple Negative Breast Neoplasms pathology, Cell Proliferation, ErbB Receptors metabolism, Glycolysis, Signal Transduction physiology, Triple Negative Breast Neoplasms metabolism, Tumor Escape
- Abstract
Oncogenic signaling reprograms cancer cell metabolism to augment the production of glycolytic metabolites in favor of tumor growth. The ability of cancer cells to evade immunosurveillance and the role of metabolic regulators in T-cell functions suggest that oncogene-induced metabolic reprogramming may be linked to immune escape. EGF signaling, frequently dysregulated in triple-negative breast cancer (TNBC), is also associated with increased glycolysis. Here, we demonstrated in TNBC cells that EGF signaling activates the first step in glycolysis, but impedes the last step, leading to an accumulation of metabolic intermediates in this pathway. Furthermore, we showed that one of these intermediates, fructose 1,6 bisphosphate (F1,6BP), directly binds to and enhances the activity of the EGFR, thereby increasing lactate excretion, which leads to inhibition of local cytotoxic T-cell activity. Notably, combining the glycolysis inhibitor 2-deoxy-d-glucose with the EGFR inhibitor gefitinib effectively suppressed TNBC cell proliferation and tumor growth. Our results illustrate how jointly targeting the EGFR/F1,6BP signaling axis may offer an immediately applicable therapeutic strategy to treat TNBC., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
13. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
- Author
-
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, and Ueno NT
- Subjects
- Animals, Apoptosis, Blotting, Western, Cell Cycle, Cell Movement, Disease Progression, Female, Fluorescent Antibody Technique, Humans, Immunoprecipitation, Inflammatory Breast Neoplasms metabolism, Inflammatory Breast Neoplasms prevention & control, Mediator Complex antagonists & inhibitors, Mediator Complex genetics, Mice, Neoplasm Invasiveness, Proto-Oncogene Proteins genetics, RNA, Messenger genetics, RNA, Small Interfering genetics, Real-Time Polymerase Chain Reaction, Receptor Protein-Tyrosine Kinases genetics, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Tumor Cells, Cultured, Axl Receptor Tyrosine Kinase, Cell Adhesion, Cell Proliferation, Inflammatory Breast Neoplasms pathology, Mediator Complex metabolism, Proto-Oncogene Proteins metabolism, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
Inflammatory breast cancer (IBC) is the most lethal form of breast cancer, but the basis for its aggressive properties are not fully understood. In this study, we report that high tumoral expression of TIG1 (RARRES1), a functionally undefined membrane protein, confers shorter survival in patients with IBC. TIG1 depletion decreased IBC cell proliferation, migration, and invasion in vitro and inhibited tumor growth of IBC cells in vivo. We identified the receptor tyrosine kinase, Axl, as a TIG1-binding protein. TIG1 interaction stablilized Axl by inhibiting its proteasome-dependent degradation. TIG1-depleted IBC cells exhibited reduced Axl expression, inactivation of NF-κB, and downregulation of matrix metalloproteinase-9, indicating that TIG1 regulates invasion of IBC cells by supporting the Axl signaling pathway in IBC cells. Consistent with these results, treatment of IBC cells with the Axl inhibitor SGI-7079 decreased their malignant properties in vitro. Finally, TIG1 expression correlated positively with Axl expression in primary human IBC specimens. Our findings establish that TIG1 positively modifies the malignant properties of IBC by supporting Axl function, advancing understanding of its development and rationalizing TIG1 and Axl as promising therapeutic targets in IBC treatment.
- Published
- 2013
- Full Text
- View/download PDF
14. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.
- Author
-
Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, and Hung MC
- Subjects
- Animals, Carrier Proteins metabolism, Cell Line, Tumor, Female, Humans, I-kappa B Kinase physiology, Inflammation genetics, Intracellular Signaling Peptides and Proteins, Lung Neoplasms secondary, Mammary Neoplasms, Experimental pathology, Mice, Mice, Inbred BALB C, NF-kappa B metabolism, Neoplasm Proteins metabolism, Transcriptional Activation, Transfection, Tumor Necrosis Factor-alpha genetics, Up-Regulation, Breast Neoplasms genetics, Breast Neoplasms pathology, Epithelial-Mesenchymal Transition, Nuclear Proteins genetics, Tumor Necrosis Factor-alpha pharmacology, Twist-Related Protein 1 genetics
- Abstract
Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial-mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α-induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB-binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB-mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment.
- Published
- 2012
- Full Text
- View/download PDF
15. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
- Author
-
Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, and Hung MC
- Subjects
- Animals, Apoptosis physiology, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Epithelial Cells pathology, Mammary Glands, Animal pathology, Mammary Neoplasms, Experimental pathology, Mice, Mice, Transgenic, Tumor Suppressor Protein p53 metabolism, Mammary Glands, Animal metabolism, Mammary Neoplasms, Experimental metabolism, Proto-Oncogene Proteins c-akt metabolism, Proto-Oncogene Proteins c-mdm2 metabolism
- Abstract
Amplification or overexpression of murine double minute 2 (MDM2) promotes a variety of human tumors by degrading tumor suppressor proteins such as p53. Phosphorylation of MDM2 on Ser(166) and Ser(186) by the survival kinase Akt inhibits p53-mediated apoptosis. However, it is unclear whether this pathway contributes to normal or malignant pathophysiology in vivo. To address these questions, we generated transgenic mice expressing the Akt-phosphorylated form of MDM2 (MDM2DDS166D/S186D) in the mammary epithelium. Activation of MDM2 delayed mammary gland involution and accelerated tumor progression in mouse mammary tumor virus/neu transgenic mice by inhibiting apoptosis in a manner associated with decreased p53 expression. Our findings offer in vivo evidence that activation of MDM2 by Akt contributes to mammary development and tumorigenesis., (© 2010 AACR.)
- Published
- 2010
- Full Text
- View/download PDF
16. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
- Author
-
Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, and Hung MC
- Subjects
- Animals, Apoptosis drug effects, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Cell Growth Processes drug effects, Cell Line, Tumor, Chlorpropamide analogs & derivatives, Chlorpropamide pharmacology, Chromones pharmacology, Colonic Neoplasms drug therapy, Colonic Neoplasms metabolism, Drug Resistance, Neoplasm, Drug Synergism, Forkhead Box Protein O3, HCT116 Cells, HT29 Cells, Humans, MAP Kinase Kinase 1 antagonists & inhibitors, MAP Kinase Kinase 1 metabolism, MAP Kinase Kinase 2 antagonists & inhibitors, MAP Kinase Kinase 2 metabolism, Melanoma drug therapy, Melanoma metabolism, Mice, Morpholines pharmacology, Neoplasms enzymology, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt metabolism, Benzimidazoles pharmacology, Forkhead Transcription Factors metabolism, Neoplasms drug therapy, Neoplasms metabolism
- Abstract
Drug resistance is a central challenge of cancer therapy that ultimately leads to treatment failure. In this study, we characterized a mechanism of drug resistance that arises to AZD6244, an established mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitor currently being evaluated in cancer clinical trials. AZD6244 enhanced the expression of transcription factor FOXO3a, which suppressed cancer cell proliferation. In AZD6244-resistant cancer cells, we observed the impaired nuclear localization of FOXO3a, reduced FOXO3a-mediated transcriptional activity, and decreased the expression of FOXO3a target gene Bim after cell treatment with AZD6244. Resistant cells could be sensitized by phosphoinositide 3-kinase (PI3K)/AKT inhibitors, which are known to enhance FOXO3a nuclear translocation. Our findings define FOXO3a as candidate marker to predict the clinical efficacy of AZD6244. Furthermore, they suggest a mechanism of resistance to MEK inhibitors that may arise in the clinic yet can be overcome by cotreatment with PI3K/AKT inhibitors., (Copyright 2010 AACR.)
- Published
- 2010
- Full Text
- View/download PDF
17. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
- Author
-
Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, and Hung MC
- Subjects
- Breast Neoplasms pathology, Cell Line, Tumor, Humans, Mutagenesis, Site-Directed, Myeloid Cell Leukemia Sequence 1 Protein, NIMA-Interacting Peptidylprolyl Isomerase, Niacinamide analogs & derivatives, Phenylurea Compounds, Phosphorylation, Sorafenib, Antineoplastic Agents pharmacology, Benzenesulfonates pharmacology, Breast Neoplasms metabolism, Down-Regulation, MAP Kinase Signaling System, Peptidylprolyl Isomerase metabolism, Proto-Oncogene Proteins c-bcl-2 physiology, Pyridines pharmacology
- Abstract
Myeloid cell leukemia-1 (Mcl-1), a Bcl-2-like antiapoptotic protein, plays a role in cell immortalization and chemoresistance in a number of human malignancies. A peptidyl-prolyl cis/trans isomerase, Pin1 is involved in many cellular events, such as cell cycle progression, cell proliferation, and differentiation through isomerizing prophosphorylated substrates. It has been reported that down-regulation of Pin1 induces apoptosis, and that Erk phosphorylates and up-regulates Mcl-1; however, the underlying mechanisms for the two phenomena are not clear yet. Here, we showed that Pin 1 stabilizes Mcl-1, which is required for Mcl-1 posphorylation by Erk. First, we found expression of Mcl-1 and Pin1 were positively correlated and associated with poor survival in human breast cancer. We then showed that Erk could phosphorylate Mcl-1 at two consensus residues, Thr 92 and 163, which is required for the association of Mcl-1 and Pin1, resulting in stabilization of Mcl-1. Moreover, Pin1 is also required for the up-regulation of Mcl-1 by Erk activation. Based on this newly identified mechanism of Mcl-1 stabilization, two strategies were used to overcome Mcl-1-mediated chemoresistance: inhibiting Erk by Sorafenib, an approved clinical anticancer drug, or knocking down Pin1 by using a SiRNA technique. In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.
- Published
- 2008
- Full Text
- View/download PDF
18. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer.
- Author
-
Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H, and Parsons R
- Subjects
- Base Sequence, Breast Neoplasms genetics, Cell Growth Processes physiology, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21 genetics, DNA-Binding Proteins, G1 Phase physiology, Gamma Rays, Gene Deletion, Humans, Molecular Sequence Data, Nuclear Proteins deficiency, Nuclear Proteins genetics, Promoter Regions, Genetic, RNA, Messenger biosynthesis, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors deficiency, Transcription Factors genetics, Up-Regulation radiation effects, Breast Neoplasms metabolism, Cyclin-Dependent Kinase Inhibitor p21 biosynthesis, Nuclear Proteins metabolism, Transcription Factors metabolism
- Abstract
Screening for tumor suppressor genes in breast cancer revealed multiple truncating mutations of PB1, which encodes the BAF180 subunit of the PBAF chromatin remodeling complex. Mutation was associated with loss of heterozygosity of the wild-type allele. BAF180 complementation of BAF180-mutant tumor cells caused G(1) arrest that was dependent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Endogenous wild-type BAF180 bound to the p21 promoter and was required for proper p21 expression and G(1) arrest after transforming growth factor-beta and gamma-radiation treatment. BAF180 thus functions on two tumor suppressor signaling pathways as a physiologic mediator of p21 expression. We conclude that BAF180 suppresses tumorigenesis, at least in part, through its ability to regulate p21.
- Published
- 2008
- Full Text
- View/download PDF
19. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.
- Author
-
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, and Hung MC
- Subjects
- Animals, Base Sequence, Breast Neoplasms genetics, Breast Neoplasms metabolism, CHO Cells, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Cell Line, Tumor, Cricetinae, Cricetulus, Dogs, Epidermal Growth Factor pharmacology, Epithelial Cells pathology, ErbB Receptors genetics, Gene Expression Regulation, Neoplastic physiology, Humans, Mesoderm pathology, Mice, Molecular Sequence Data, Promoter Regions, Genetic, STAT3 Transcription Factor genetics, Swiss 3T3 Cells, Twist-Related Protein 1 genetics, Up-Regulation, Breast Neoplasms pathology, Carcinoma, Squamous Cell pathology, ErbB Receptors metabolism, STAT3 Transcription Factor metabolism, Twist-Related Protein 1 biosynthesis
- Abstract
Aberrant epidermal growth factor receptor (EGFR) signaling is a major cause of tumor progression and metastasis; the underlying mechanisms, however, are not well understood. In particular, it remains elusive whether deregulated EGFR pathway is involved in epithelial-mesenchymal transition (EMT), an early event that occurs during metastasis of cancers of an epithelial origin. Here, we show that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology. EGF reduced E-cadherin expression and increased that of mesenchymal proteins. In search of a downstream mediator that may account for EGF-induced EMT, we focused on transcription repressors of E-cadherin, TWIST, SLUG, and Snail and found that cancer cells express high levels of TWIST and that EGF enhances its expression. EGF significantly increases TWIST transcripts and protein in EGFR-expressing lines. Forced expression of EGFR reactivates TWIST expression in EGFR-null cells. TWIST expression is suppressed by EGFR and Janus-activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) inhibitors, but not significantly by those targeting phosphoinositide-3 kinase and MEK/ERK. Furthermore, constitutively active STAT3 significantly activates the TWIST promoter, whereas the JAK/STAT3 inhibitor and dominant-negative STAT3 suppressed TWIST promoter. Deletion/mutation studies further show that a 26-bp promoter region contains putative STAT3 elements required for the EGF-responsiveness of the TWIST promoter. Chromatin immunoprecipitation assays further show that EGF induces binding of nuclear STAT3 to the TWIST promoter. Immunohistochemical analysis of 130 primary breast carcinomas indicates positive correlations between non-nuclear EGFR and TWIST and between phosphorylated STAT3 and TWIST. Together, we report here that EGF/EGFR signaling pathways induce cancer cell EMT via STAT3-mediated TWIST gene expression.
- Published
- 2007
- Full Text
- View/download PDF
20. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion.
- Author
-
Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC, and Zhao J
- Subjects
- Blotting, Western, Breast Neoplasms metabolism, Cadherins genetics, Cadherins metabolism, Cell Differentiation, Cell Movement, Chromatin Immunoprecipitation, Epithelial Cells metabolism, Fluorescent Antibody Technique, Humans, Kruppel-Like Transcription Factors, Luciferases metabolism, Mesoderm metabolism, Neoplasm Invasiveness, Promoter Regions, Genetic genetics, RNA, Small Interfering pharmacology, Reverse Transcriptase Polymerase Chain Reaction, Snail Family Transcription Factors, Transcription Factors genetics, Transcription Factors metabolism, Tumor Cells, Cultured, Breast Neoplasms pathology, Cell Transformation, Neoplastic pathology, DNA-Binding Proteins physiology, Epithelial Cells pathology, Mesoderm pathology, Repressor Proteins physiology
- Abstract
Tumor invasion and metastasis are the main causes of death from cancer. Epithelial to mesenchymal transition (EMT) is a determining step for a cancer cell to progress from a noninvasive to invasive state. Krüppel-like factor 8 (KLF8) plays a key role in oncogenic transformation and is highly overexpressed in several types of invasive human cancer, including breast cancer. To understand the role of KLF8 in regulating the progression of human breast cancer, we first established stable expression of KLF8 in an immortalized normal human breast epithelial cell line. We found that KLF8 strongly induced EMT and enhanced motility and invasiveness in the cells, by analyzing changes in cell morphology and epithelial and mesenchymal marker proteins, and using cell migration and Matrigel invasion assays. Chromatin immunoprecipitations (ChIP), oligonucleotide precipitations, and promoter-reporter assays showed that KLF8 directly bound and repressed the promoter of E-cadherin independent of E boxes in the promoter and Snail expression. Aberrant elevation of KLF8 expression is highly correlated with the decrease in E-cadherin expression in the invasive human breast cancer. Blocking KLF8 expression by RNA interference restored E-cadherin expression in the cancer cells and strongly inhibited the cell invasiveness. This work identifies KLF8 as a novel EMT-regulating transcription factor that opens a new avenue in EMT research and suggests an important role for KLF8 in human breast cancer invasion and metastasis.
- Published
- 2007
- Full Text
- View/download PDF
21. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.
- Author
-
Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, Lee DF, Yang JY, Xie X, Liu JC, and Hung MC
- Subjects
- Breast Neoplasms enzymology, Cell Line, Tumor, Down-Regulation, Enzyme Activation, Glycogen Synthase Kinase 3 antagonists & inhibitors, Glycogen Synthase Kinase 3 beta, Humans, Insulin-Like Growth Factor I pharmacology, Myeloid Cell Leukemia Sequence 1 Protein, Neoplasm Proteins biosynthesis, Phosphorylation, Prognosis, Proteasome Endopeptidase Complex metabolism, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Staurosporine pharmacology, Ultraviolet Rays, Breast Neoplasms metabolism, Glycogen Synthase Kinase 3 metabolism, Neoplasm Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism
- Abstract
Myeloid cell leukemia-1 (Mcl-1), an antiapoptotic Bcl-2 family member, is overexpressed in many types of human cancer and associates with cell immortalization, malignant transformation, and chemoresistance. Glycogen synthase kinase-3beta (GSK-3beta), a key component of the Wnt signaling pathway, is involved in multiple physiologic processes such as protein synthesis, tumorigenesis, and apoptosis. Here, we report that expression of Mcl-1 was correlated with phosphorylated GSK-3beta (p-GSK-3beta) at Ser(9) (an inactivated form of GSK-3beta) in multiple cancer cell lines and primary human cancer samples. In addition, Mcl-1 was strikingly linked with poor prognosis of human breast cancer, in which the high level of Mcl-1 was related to high tumor grade and poor survival of breast cancer patients. Furthermore, we found that activation of GSK-3beta could down-regulate Mcl-1 and was required for proteasome-mediated Mcl-1 degradation. Under some physiologic conditions, such as UV irradiation, anticancer drug treatment, and inhibition of growth factor pathways, Mcl-1 was down-regulated through activation of GSK-3beta. Our results indicate that Mcl-1 stabilization by GSK-3beta inactivation could be involved in tumorigenesis and serve as a useful prognostic marker for human breast cancer.
- Published
- 2007
- Full Text
- View/download PDF
22. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
- Author
-
Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, and Spector NL
- Subjects
- Antineoplastic Agents pharmacology, Apoptosis drug effects, Apoptosis physiology, Breast Neoplasms enzymology, Breast Neoplasms genetics, Cell Line, Tumor, Humans, Lapatinib, PTEN Phosphohydrolase genetics, Phosphatidylinositol 3-Kinases metabolism, Phosphorylation, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Signal Transduction drug effects, Breast Neoplasms drug therapy, PTEN Phosphohydrolase deficiency, Quinazolines pharmacology, Receptor, ErbB-2 biosynthesis
- Abstract
Trastuzumab antitumor activity in ErbB2-overexpressing breast cancers seems to be dependent upon the presence of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a phosphatase that dampens phosphatidylinositol 3-kinase-Akt signaling. Consequently, PTEN deficiency, which occurs in 50% of breast cancers, predicts for resistance to trastuzumab monotherapy. Here, we show that lapatinib, a small-molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, exerts its antitumor activity in a PTEN-independent manner. Steady-state phosphorylated ErbB2 (p-ErbB2) and p-Akt (S473) protein levels were inhibited within 30 min following lapatinib but not in response to trastuzumab in BT474 and Au565 cells (two ErbB2-overexpressing breast cancer cell lines that are sensitive to the proapoptotic effects of lapatinib). Whereas trastuzumab reportedly inhibits SRC phosphorylation (Y416), which in turn reduced SRC-ErbB2 protein interactions, lapatinib had no effect on either variable. To assess the potential functional role that PTEN might play in lapatinib antitumor activity, we selectively knocked down PTEN in BT474 and Au565 cells using small interfering RNA transfection. Loss of PTEN did not affect induction of tumor cell apoptosis by lapatinib in either cell line. In addition, lapatinib inhibited Akt phosphorylation in MDA-MB-468 cells, an ErbB1-expressing/ErbB2 non-overexpressing breast cancer line, despite their PTEN-null status. Moreover, patients with ErbB2-overexpressing inflammatory breast cancers responded to lapatinib monotherapy regardless of PTEN status. Thus, lapatinib seems to exert its antitumor activity in ErbB2-overexpressing breast cancers in a PTEN-independent manner. These data emphasize the importance of assessing PTEN status in tumors when selecting ErbB2-targeted therapies in patients with breast cancer.
- Published
- 2007
- Full Text
- View/download PDF
23. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
- Author
-
Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, and Spector NL
- Subjects
- Apoptosis drug effects, Apoptosis physiology, Breast Neoplasms genetics, Cell Line, Tumor, Down-Regulation, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Humans, Inhibitor of Apoptosis Proteins, Lapatinib, Microtubule-Associated Proteins antagonists & inhibitors, Microtubule-Associated Proteins genetics, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Phosphatidylinositol 3-Kinases metabolism, Quinazolines pharmacology, RNA Interference, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 biosynthesis, Receptor, ErbB-2 genetics, Receptor, ErbB-3 physiology, Signal Transduction drug effects, Signal Transduction genetics, Survivin, Breast Neoplasms metabolism, Microtubule-Associated Proteins biosynthesis, Neoplasm Proteins biosynthesis, Receptor, ErbB-2 physiology
- Abstract
In breast cancer, overexpression of ErbB2 or aberrant regulation of survivin, a member of the inhibitor of apoptosis family, is associated with resistance to chemo/hormone therapy and predicts for a poor clinical outcome. A functional link between the two predictive factors has not been previously shown. Here, using genetic and pharmacologic approaches to block ErbB2 signaling, we show that ErbB2 regulates survivin protein expression in ErbB2-overexpressing breast cancer cells. Selective knockdown of ErbB2 using small interfering RNA markedly reduced survivin protein, resulting in apoptosis of ErbB2-overexpressing breast cancer cell lines such as BT474. Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis. The effect of lapatinib on survivin seems to be predominantly posttranslational, mediated by ubiquitin-proteosome degradation as lactacystin, a proteosome inhibitor, reverses these effects. Furthermore, lapatinib down-regulated the expression of His-tagged survivin, which was under the transcriptional control of a heterologous promoter, providing additional evidence supporting a posttranslational mechanism of regulation. In contrast, trastuzumab and gefitinib failed to down-regulate survivin in ErbB2-overexpressing breast cancer cells. Importantly, the clinical relevance of these findings was illustrated in patients with ErbB2-overexpressing breast cancer whose clinical response to lapatinib was associated with marked inhibition of survivin in their tumors. These findings shed new light on the mechanism by which ErbB2 overexpression protects against apoptotic stimuli in breast cancer and identifies therapeutic interventions to improve clinical outcomes in these aggressive tumors.
- Published
- 2006
- Full Text
- View/download PDF
24. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.
- Author
-
Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, and Hung MC
- Subjects
- Breast Neoplasms mortality, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Cell Nucleus pathology, Cyclin D1 analysis, ErbB Receptors analysis, Female, Humans, Ki-67 Antigen analysis, Mouth Neoplasms pathology, Survival Analysis, Breast Neoplasms pathology, ErbB Receptors genetics
- Abstract
Epidermal growth factor receptor (EGFR) has been detected in the nucleus of cancer cells and primary tumors for decades. While localized in the nucleus, EGFR functions as a transcriptional regulator resulting in the activation of the cyclin D1 gene. Despite nuclear accumulation of EGFR is linked to increased DNA synthesis and proliferative potential, the pathological significance of nuclear EGFR, however, remains uninvestigated. Furthermore, expression of EGFR has not provided a consistent predictive value for survival of breast cancer patients. Here, we analyzed 130 breast carcinomas via immunohistochemical analyses for the levels of nuclear and non-nuclear EGFR. We found 37.7% of the cohort immunostained positively for nuclear EGFR and 6.9% with high levels of expression. Importantly, Kaplan-Meier survival analysis and log-rank test revealed a significant inverse correlation between high nuclear EGFR and overall survival (P = 0.009). Expression of nuclear EGFR correlated positively with increased levels of cyclin D1 and Ki-67, both are indicators for cell proliferation. In contrast, expression of non-nuclear EGFR did not significantly correlate with those of cyclin D1 and Ki-67 or the overall survival rate. In addition, we analyzed 37 oral squamous carcinomas for EGFR expression and found 24.3% of the cases to contain moderate/high levels of nuclear EGFR. Taken together, our findings indicate pathological significance of nuclear EGFR and may have important clinical implication.
- Published
- 2005
25. Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.
- Author
-
Chen Y, Shi G, Xia W, Kong C, Zhao S, Gaw AF, Chen EY, Yang GP, Giaccia AJ, Le QT, and Koong AC
- Subjects
- Cell Hypoxia, Cell Line, Tumor, Cortactin, Female, Heat-Shock Proteins biosynthesis, Humans, I-kappa B Kinase, Male, Microfilament Proteins biosynthesis, Middle Aged, Oxygen metabolism, Protein Serine-Threonine Kinases biosynthesis, Proteomics, Tissue Array Analysis, Up-Regulation, Carcinoma, Squamous Cell metabolism, Head and Neck Neoplasms metabolism, Neoplasm Proteins biosynthesis
- Abstract
Hypoxia within solid tumors decreases therapeutic efficacy, and identification of hypoxia markers may influence the choice of therapeutic modality. Here, we used a proteomic approach to identify hypoxia-regulated proteins and validated their use as endogenous indicators of tumor hypoxia. Using two-dimensional gel electrophoresis and PowerBlot (antibody-based array), we identified a group of 20 proteins that are increased >/=1.5-fold during hypoxia. The majority of these proteins such as IkappaB kinase beta (IKKbeta), MKK3b, highly expressed in cancer (HEC), density-regulated protein 1, P150(glued), nuclear transport factor 2, binder of ARL 2, Paxillin, and transcription termination factor I have not been previously reported to be hypoxia inducible. The increase in these proteins under hypoxia was mediated through posttranscriptional mechanisms. We additionally characterized the role of IKKbeta, a regulator of the nuclear factor-kappaB transcription factor, during hypoxia. We demonstrated that IKKbeta mediates cell survival during hypoxia and is induced in a variety of squamous cell carcinoma cell lines. Furthermore, we showed that IKKbeta expression from tumor specimens correlated with tumor oxygenation in patients with head and neck squamous cell carcinomas. These data suggest that IKKbeta is a novel endogenous marker of tumor hypoxia and may represent a new target for anticancer therapy.
- Published
- 2004
- Full Text
- View/download PDF
26. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy.
- Author
-
Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, and Hung MC
- Subjects
- Cell Line, Tumor, Female, Genes, jun, Humans, Ovarian Neoplasms genetics, Transcription, Genetic, Ceruloplasmin genetics, Genetic Therapy, Ovarian Neoplasms therapy, Promoter Regions, Genetic
- Abstract
Gene therapy provides a novel treatment approach to cancer patients. Ideally, expression of therapeutic genes driven by cancer-specific promoters would only target tumors resulting in minimal toxicity to normal tissues. While there is a need of more effective and tolerable treatments for ovarian cancer patients, we aimed to identify gene promoters with high activity in ovarian tumors that can be potentially used in gene therapy to drive the expression of a therapeutic gene in tumors. To identify such promoters, a literature search was performed to reveal genes that are preferentially expressed in ovarian cancer compared with normal ovarian tissue. We found that the ceruloplasmin promoter drove up to 30-fold higher luciferase expression in ovarian cancer cells compared with immortalized normal cells. Furthermore, deletion studies revealed an activator protein-1 (AP-1) site in the ceruloplasmin promoter to be critical for optimal ceruloplasmin promoter activity. Ceruloplasmin promoter activity was significantly activated by 1-O-tetradecanoyl phorbol-13-acetate, a c-jun activator, and conversely suppressed by SP600125, a c-jun inhibitor. Consistently, the ceruloplasmin AP-1 site was specifically recognized by c-jun both in vitro and in vivo. Immunohistochemical analyses of human ovarian cancer specimens showed a direct correlation (r = 0.7, P = 0.007) between expression levels of c-jun and ceruloplasmin. In nude mice carrying SKOV3.ip1 xenografts, the ceruloplasmin promoter demonstrated significantly higher activities in tumors compared with normal organs. Together, these results suggest that the ceruloplasmin promoter activity is significantly enhanced in ovarian cancer and therefore may be exploited as a promising cancer-specific promoter in developing new gene therapy strategies for ovarian cancer.
- Published
- 2004
- Full Text
- View/download PDF
27. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
- Author
-
Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, and Hung MC
- Subjects
- Adenovirus E1A Proteins biosynthesis, Adenovirus E1A Proteins physiology, Antineoplastic Agents, Phytogenic pharmacology, Apoptosis drug effects, Apoptosis genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Division genetics, Combined Modality Therapy, DNA administration & dosage, DNA genetics, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms genetics, Head and Neck Neoplasms pathology, Humans, Liposomes administration & dosage, Paclitaxel pharmacology, Xenograft Model Antitumor Assays, Adenovirus E1A Proteins genetics, Breast Neoplasms therapy, Genetic Therapy methods, Head and Neck Neoplasms therapy
- Abstract
The adenovirus type 5 E1A protein has been demonstrated to elicit antitumor effects through the induction of apoptosis, inhibition of cell cycle progression, induction of differentiated epithelial phenotypes, repression of oncogene expression and function, and sensitization to chemotherapeutic agents and radiation. These unique properties have led to use of the E1A gene in adenoviral and lipid-based gene therapy systems, and it has demonstrated antitumor effects in tumor xenograft model systems. However, the delivery systems used in those studies are best suited for local or intratumoral delivery rather than systemic delivery. Because the effective treatment of many primary tumors as well as metastatic disease requires systemic delivery systems, a novel gene delivery system composed of liposome/protamine/DNA (LPD) was investigated for systemic delivery of the E1A gene. Athymic nude mice bearing human breast (MDA-MB-361) or head and neck (WSUHN-31) tumor xenografts were treated i.v. with LPD-E1A, and the expression of E1A protein and effects on tumor growth were assessed. In the MDA-MB-361 breast model, expression of E1A protein was detected in the tumors after LPD-E1A treatment, which was associated with down-regulation of HER-2/neu protein expression and the presence of apoptotic cells. Tumor volume was also smaller in mice treated with LPD-E1A than in controls in both of the xenograft models. Lastly, LPD-E1A in combination with paclitaxel was more effective than LPD-E1A or paclitaxel alone in the MDA-MB-361 model. Additional preclinical and clinical development of LPD-E1A is warranted for the treatment of advanced or metastatic cancer.
- Published
- 2002
28. The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression.
- Author
-
Deng J, Kloosterbooer F, Xia W, and Hung MC
- Subjects
- Adenovirus E1A Proteins genetics, Adenovirus E1A Proteins metabolism, Animals, Apoptosis physiology, Conserved Sequence, Female, Genes, Tumor Suppressor, Melanoma, Experimental genetics, Melanoma, Experimental pathology, Melanoma, Experimental virology, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Nude, Protein Binding, Protein Structure, Tertiary, Retinoblastoma Protein metabolism, Transfection, Adenovirus E1A Proteins physiology
- Abstract
Adenovirus E1A has been shown to suppress tumor growth and induce apoptosis in response to stress. To determine the mechanisms and regions of E1A that mediate these functions, we characterized stable transfectants of various E1A mutants in murine melanoma cells both in vitro and in vivo. Three E1A-mutant constructs were used in this study, those having a single deletion at either the NH(2)-terminal (dl1101) or conserved region 2 (CR2) domain (dl1108), or double deletions at both domains (dl0108). The in vitro study showed that the CR2 domain is required for E1A-mediated apoptosis, whereas the NH(2)-terminal domain is dispensable. The in vivo study showed that dl1101 and dl1108 were still able to suppress tumor growth, whereas dl0108 lost tumor-suppressive activity. By in situ immunohistostaining, we found that factor VIII, a marker for angiogenesis, was greatly suppressed in dl1108 transfectants that are resistant to apoptosis. Thus, inhibition of angiogenesis is involved in the NH(2)-terminal domain of E1A. In conclusion, we suggest that the NH(2)-terminal and CR2 domain of E1A mediate two distinct mechanisms of tumor suppression.
- Published
- 2002
29. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
- Author
-
Xia W, Unger P, Miller L, Nelson J, and Gelman IH
- Subjects
- A Kinase Anchor Proteins, Animals, Biomarkers, Tumor, Cell Differentiation, Cell Division drug effects, Chromosome Banding, Chromosome Mapping, Chromosomes, Human, Pair 6 genetics, Female, Gene Expression Regulation, Neoplastic drug effects, HeLa Cells, Humans, In Situ Hybridization, Fluorescence, Male, Mice, Mice, Nude, Mitogens physiology, Molecular Weight, Neoplasm Metastasis genetics, Neoplasm Metastasis pathology, Neoplasm Transplantation, Neoplasms, Experimental genetics, Neoplasms, Experimental pathology, Prostatic Neoplasms pathology, Protein Isoforms chemistry, Protein Isoforms genetics, Proteins genetics, RNA, Neoplasm genetics, RNA, Neoplasm metabolism, Rats, Tetracycline pharmacology, Transplantation, Heterologous, Tumor Cells, Cultured, Cell Cycle Proteins, Mitogens genetics, Prostatic Neoplasms genetics
- Abstract
The molecular mechanisms leading to prostate cancer remain poorly understood, especially concerning the progression to the metastatic form. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, is likely the rodent orthologue of human Gravin/AKAP12, a scaffolding protein for protein kinases A and C. Gravin was mapped as a single-copy gene to 6q24-25.2, a hotspot for deletion in advanced prostate cancer, and therefore, we investigated the role of SSeCKS/Gravin in prostate oncogenesis. SSeCKS/Gravin protein was detected in untransformed rat and human prostate epithelial cell lines EP12 and PZ-HPV-7, respectively, and in human prostatic epithelium, especially basal epithelial cells. In contrast, SSeCKS/Gravin protein and RNA levels were severely reduced in human (PC-3, PPC-1, LNCaP, DU145, and TSU) and rat Dunning (AT3.1 and MatLyLu) prostate cancer cell lines. The regulated reexpression of SSeCKS in MatLyLu cells induced filopodia-like projections and a decrease in anchorage-independent growth. In nude mice, SSeCKS reexpression slightly decreased primary-site tumor growth but severely decreased the formation of lung metastases. Primary-site tumors that progressed lost regulated SSeCKS reexpression. SSeCKS/Gravin expression was detected in benign human prostatic lesions and well-differentiated carcinomas but not in undifferentiated lesions with Gleason sums > or =6. Our data suggest a role for the loss of SSeCKS/Gravin in the metastatic progression of human prostate cancer.
- Published
- 2001
30. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice.
- Author
-
Xu F, Xia W, Luo RZ, Peng H, Zhao S, Dai J, Long Y, Zou L, Le W, Liu J, Parlow AF, Hung MC, Bast RC Jr, and Yu Y
- Subjects
- Animals, Body Weight genetics, Cytomegalovirus genetics, Estradiol blood, Female, Gene Expression, Growth Hormone blood, Growth Inhibitors biosynthesis, Growth Inhibitors physiology, Male, Mammary Glands, Animal growth & development, Mammary Glands, Animal metabolism, Mice, Mice, Inbred ICR, Mice, Transgenic, Ovary growth & development, Ovary physiology, Phenotype, Postpartum Period, Pregnancy, Progesterone blood, Prolactin blood, Prolactin metabolism, Promoter Regions, Genetic, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Genes, Tumor Suppressor physiology, Growth Inhibitors genetics, Lactation Disorders genetics, Mammary Glands, Animal physiology, rho GTP-Binding Proteins
- Abstract
ARHI is a novel imprinted tumor suppressor gene. To study its function in vivo, we have developed transgenic mice that overexpress ARHI. Offspring bearing the transgene had significantly lower body weights than did nontransgenic littermates. In addition, strong expression of the ARHI transgene was associated with greatly impaired mammary gland development and lactation, failure of ovarian folliculogenesis resulting in decreased fertility, loss of neurons in the cerebellar cortex, and impaired development of the thymus. Decrease in body size and defects in the mammary glands correlated with the level of transgene expression. Immunohistochemical analysis indicated that expression of prolactin (PRL), but not growth hormone, was lower in the pituitary glands of mice with defective mammary gland development. The defect in pregnancy-associated mammary tissue proliferation was associated with decreased serum PRL and progesterone levels. Moreover, lower levels of estrogen receptor and progesterone receptor were observed in postpartum mammary glands and in the ovaries of mice that overexpressed ARHI. Our data suggest that ARHI can inhibit PRL secretion and act as a negative regulator in murine growth and development.
- Published
- 2000
31. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression.
- Author
-
Shao R, Xia W, and Hung MC
- Subjects
- Animals, Cells, Cultured, Coculture Techniques, Female, Humans, Immunohistochemistry, In Situ Nick-End Labeling, Mice, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental pathology, Thymidine metabolism, Time Factors, Transfection, Tumor Cells, Cultured, Adenovirus E1A Proteins pharmacology, Apoptosis drug effects, Neoplasms, Experimental blood supply, Neovascularization, Pathologic drug therapy
- Abstract
Adenovirus type 5 E1A has been implicated in mediation of tumor suppression. Preclinical gene therapy studies have additionally shown that complete growth suppression can be achieved by incomplete transfer of E1A into tumors, suggesting that a bystander effect may also be associated with E1A. In this study, we investigated the E1A-mediated bystander effect and the mechanisms that may be associated with it. By s.c. inoculating nude mice with a mixture of E1A transfectants and parental cells, we found that the E1A transfectants exhibited a bystander effect on inhibition of tumor growth. We further showed that E1A mediated suppression of angiogenesis and induction of apoptosis in the tumors, likely contributing to the bystander effect. In addition, coculture of E1A transfectants and parental cells in a Transwell unit led to growth retardation and apoptosis mediated by the supernatant in the parental cells, indicating that a secreted factor may also contribute to the bystander effect. Taken together, our results suggested that E1A mediates a bystander effect on tumor suppression by inhibiting angiogenesis and inducing apoptosis.
- Published
- 2000
32. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas.
- Author
-
Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, Agarwal RP, Xia W, Boise LH, Podack E, and Harrington WJ Jr
- Subjects
- Burkitt Lymphoma metabolism, Caspases metabolism, Dose-Response Relationship, Drug, Flow Cytometry, Herpesvirus 4, Human metabolism, Humans, Lymphoma, AIDS-Related pathology, Lymphoma, Non-Hodgkin pathology, Phosphorylation, Proto-Oncogene Proteins c-bcl-2 metabolism, Time Factors, Transfection, Tumor Cells, Cultured, Up-Regulation, fas Receptor metabolism, Apoptosis, Herpesvirus 8, Human metabolism, Interferon-alpha pharmacology, Lymphoma metabolism, Zidovudine pharmacology
- Abstract
Lymphoproliferative diseases that occur in immunocompromised patients are frequently associated with herpesviruses. These patients often fare poorly after treatment with conventional chemotherapy. We reported previously that patients with AIDS-related Burkitt's lymphoma (BL) responded to parenteral azidothymidine (AZT) and IFN-alpha. We found that EBV-positive lymphoma cells derived from these patients cultured with AZT express CD95 and undergo apoptosis. AZT-mediated apoptosis was caspase dependent and occurred despite Fas receptor blockade. In contrast, EBV-negative lymphomas were resistant to AZT-induced apoptosis, as were EBV-positive lymphomas that expressed high levels of bcl-2. Primary effusion lymphoma (PEL) cell lines infected with human herpesvirus type 8 required IFN-alpha to potentiate AZT-induced apoptosis. IFN-alpha did not up-regulate CD95 in BL or PEL but did induce expression of the death receptor ligand, CD95 ligand. AZT-sensitive lymphomas also accumulated significantly higher intracellular AZT monophosphate than did resistant lymphomas. Our data demonstrated distinct apoptotic responses to AZT and IFN-alpha in herpesvirus-associated lymphomas. EBV-positive BL cells that expressed low BCL-2 levels were sensitive to AZT alone; PEL cells required the addition of IFN-alpha to enhance apoptosis, and EBV-negative lymphomas were insensitive to both agents. AZT-sensitive BL cells transfected with BCL-2 became resistant. Susceptibility to antivirus-mediated apoptosis may be exploited to improve the therapy of certain herpesvirus-associated lymphomas.
- Published
- 1999
33. Rat dihydrodiol dehydrogenase: complexity of gene structure and tissue-specific and sexually dimorphic gene expression.
- Author
-
Hou YT, Xia W, Pawlowski JE, and Penning TM
- Subjects
- Animals, Blotting, Northern, Blotting, Southern, Female, Intestine, Small enzymology, Lung enzymology, Male, RNA, Messenger analysis, Rats, Rats, Sprague-Dawley, Alcohol Oxidoreductases genetics, Gene Expression Regulation, Enzymologic genetics, Liver enzymology, Oxidoreductases, Oxidoreductases Acting on CH-CH Group Donors, Sex Characteristics
- Abstract
Dihydrodiol dehydrogenase (DD; EC 1.3.1.20) catalyzes a novel pathway of polycyclic aromatic hydrocarbon (PAH) metabolism in which trans-dihydrodiols (proximate carcinogens) are oxidized to reactive o-quinones which are cytotoxic and genotoxic. In this study, the complementary DNA for rat liver DD was used to examine the structure and regulation of the DD gene. Southern analysis of rat genomic DNA confirmed that DD is a member of the multigene aldo-keto reductase superfamily. Conservative estimates indicate that the rat DD gene is at least 20-25 kilobases in length. Northern analysis showed that the rat liver transcript was 2.4 kilobases whereas the complementary DNA contains an open-reading frame of 966 nucleotides. Primer extension of male and female polyadenylated RNA indicated that the major transcription start sites are only 53 and 54 base pairs upstream from the translation start site, confirming that the RNA has a very long 3'-untranslated region. In male and female tissues, 2.4 kilobase transcripts predominate in liver, small intestine, and lung, which is consistent with a role for the enzyme in PAH metabolism. Transcripts were also detected in male (prostate)- and female (ovary, mammary gland, and uterus)-specific tissues. In the ovary, two transcripts were observed of 2.4 and 1.4 kilobases in length. Using benzenedihydrodiol as a model substrate for PAH trans-dihydrodiols, highest levels of DD activity were observed in the liver and small intestine of both sexes. Enzyme activity is 2.5-fold higher in the female liver versus the male liver. This sexual dimorphism can be explained by increases in the DD mRNA and enzyme protein as measured by dot-blot and immunotitration analyses, respectively. The latter measurements indicate that DD represents 1.0% of the soluble protein in female liver but is only 0.5% of the soluble protein in male liver. Hormonal ablation (ovariectomy and hypophysectomy) abolishes the sexual dimorphism observed in levels of DD mRNA, enzyme protein, and enzyme activity. Administration of estrogens to males is sufficient to establish the female pattern of gene expression. These data indicate that DD gene expression is hormonally regulated, that estrogens exert their effect at the level of the mRNA, and that aldo-keto reductases involved in PAH metabolism may have their expression regulated by female sex hormones.
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.